To examine the clinical significance of our findings, we also performed triple‐immunostaining of CD34, α‐SMA, and YY1 on tumor sections derived from our EGFR mutated NSCLC patient cohort. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.